Kliniske resultater ved uge 52 Kliniske og virologiske effekt- endepunkter blev vurderet separat i de HBeAg- positive og HBeAg - negative patientpopulationer.
Clinical results at week 52 Clinical and virological efficacy endpoints were evaluated separately in the HBeAg-positive and HBeAg-negative patient populations.